DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis

Stock Information for DURECT Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About DURECT Corporation

Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VBTX, PVBC, DRRX on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate Merger of VBTX, CFSB, PVBC, and DRRX
DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NSC, SNV, DRRX, PNFP on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of DURECT Corporation (NASDAQ: DRRX)
DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.